{"id":7254,"date":"2013-07-23T19:05:04","date_gmt":"2013-07-24T00:05:04","guid":{"rendered":"http:\/\/medicinainterna.com.mx\/?p=7254"},"modified":"2013-07-23T19:05:04","modified_gmt":"2013-07-24T00:05:04","slug":"estadificacion-de-la-leucemia-linfoide-habitual-de-celulas-b-raibinet","status":"publish","type":"post","link":"https:\/\/medicinainterna.com.mx\/?p=7254","title":{"rendered":"Estadificaci\u00f3n de la leucemia linfoide habitual de c\u00e9lulas B (RAI\/BINET)."},"content":{"rendered":"

<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Estadio<\/i><\/b><\/td>\nManifestaciones cl\u00ednicas<\/i><\/b><\/td>\nSupervivencia media, a\u00f1os<\/i><\/b><\/td>\n<\/tr>\n
SISTEMA RAI<\/i><\/b><\/td>\n\u00a0<\/i><\/b><\/td>\n\n

\u00a0<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n

0: Riesgo bajo<\/td>\nS\u00f3lo linfocitosis en sangre y m\u00e9dula \u00f3sea<\/td>\n\n

>10<\/p>\n<\/td>\n<\/tr>\n

I: Riesgo intermedio<\/td>\nLinfocitosis + linfadenopat\u00edas + esplenomegalia: \u00b1 hepatomegalia<\/td>\n\n

7<\/p>\n<\/td>\n<\/tr>\n

II<\/td>\n <\/td>\n\n

\n<\/td>\n<\/tr>\n

III: Riesgo alto<\/td>\nLinfocitosis + anemia<\/td>\n\n

1.5<\/p>\n<\/td>\n<\/tr>\n

IV<\/td>\n <\/td>\n\n

Linfocitosis + trombocitopenia<\/p>\n<\/td>\n<\/tr>\n

SISTEMA DE BINET<\/i><\/b><\/td>\n\u00a0<\/i><\/b><\/td>\n\n

\u00a0<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n

A<\/td>\nAdenopat\u00edas palpables en menos de tres zonas; sin anemia ni trombocitopenia<\/td>\n\n

>10<\/p>\n<\/td>\n<\/tr>\n

B<\/td>\nTres o m\u00e1s zonas ganglionares afectadas; sin anemia ni trombocitopenia<\/td>\n\n

7<\/p>\n<\/td>\n<\/tr>\n

C<\/td>\nHemoglobina 10 g\/100 ml, o plaquetas <100 000\/ l<\/td>\n\n

2<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Fuente: Harrison, T. Principios de Medicina Interna 1\u00aa edici\u00f3n. Mc Graw-Hill Interamericana.<\/p>\n","protected":false},"excerpt":{"rendered":"

Estadio Manifestaciones cl\u00ednicas Supervivencia media, a\u00f1os SISTEMA RAI \u00a0 \u00a0 0: Riesgo bajo S\u00f3lo linfocitosis en sangre y m\u00e9dula \u00f3sea >10 I: Riesgo intermedio Linfocitosis + linfadenopat\u00edas + esplenomegalia: \u00b1 hepatomegalia 7 II   III: Riesgo alto Linfocitosis + anemia 1.5 IV   Linfocitosis + trombocitopenia SISTEMA DE BINET \u00a0 \u00a0 A Adenopat\u00edas palpables en … Continue reading “Estadificaci\u00f3n de la leucemia linfoide habitual de c\u00e9lulas B (RAI\/BINET).”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-7254","post","type-post","status-publish","format-standard","hentry","category-hematologia"],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7254"}],"version-history":[{"count":0,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=\/wp\/v2\/posts\/7254\/revisions"}],"wp:attachment":[{"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicinainterna.com.mx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}